Combining EZH2 and HDAC inhibitors to target castration-resistant prostate cancers

Jonathan B Coulter; Hariharan Easwaran

doi:10.1371/journal.pbio.3002081

Combining EZH2 and HDAC inhibitors to target castration-resistant prostate cancers

PLoS Biol. 2023 Apr 27;21(4):e3002081. doi: 10.1371/journal.pbio.3002081. eCollection 2023 Apr.

Authors

Jonathan B Coulter¹, Hariharan Easwaran²

Affiliations

¹ The Brady Urological Institute, Johns Hopkins University School of Medicine, Baltimore, Maryland, United States of America.
² Cancer Genetics and Epigenetics, Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, Maryland, United States of America.

Abstract

Development of resistance in castration-resistant prostate cancer (CRPC) involves epigenetic pathways. A new study in PLOS Biology demonstrates that combined therapy targeting enhancer of zeste homolog 2 (EZH2) and histone deacetylases (HDACs) may sensitize CRPC to both epigenetic and standard therapies.

Copyright: © 2023 Coulter, Easwaran. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Publication types

Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Comment

MeSH terms

Cell Line, Tumor
Enhancer of Zeste Homolog 2 Protein / genetics
Epigenesis, Genetic / drug effects
Histone Deacetylase Inhibitors / pharmacology
Histone Deacetylase Inhibitors / therapeutic use
Humans
Male
Prostatic Neoplasms, Castration-Resistant* / drug therapy
Prostatic Neoplasms, Castration-Resistant* / genetics
Prostatic Neoplasms, Castration-Resistant* / metabolism

Substances

Enhancer of Zeste Homolog 2 Protein
Histone Deacetylase Inhibitors
EZH2 protein, human

Abstract

Publication types

MeSH terms

Substances

Grants and funding